Pfizer reported earnings of $0.87 per share for the third quarter of its 2026 fiscal year, above the forecast of $0.73. The gap is $0.14, or 18.8% above the forecast. Revenue came in at $16.6 billion, against a forecast of $16.0 billion.
Revenue against forecast
Revenue was $552.2 million above the forecast, which is 3.4% above the revenue forecast. The company’s fiscal year may not match the calendar year, so the quarter is Pfizer’s own third quarter of fiscal 2026. The results were released on 3 November 2026 and taken from the company’s own filing.
Market backdrop
In markets the same day, the Nasdaq Composite stood at 25,164.31 points at the close of 2 November 2026, down 1.07% from the previous close. That was its lowest level in 31 days.
Related: Apple EPS $2.05 Beats Forecast; Revenue Trails · Chevron Q3 EPS $5.28 Beats $4.93 Forecast
Source: Pfizer | Data: Nasdaq
